The notices it replaced
- Reissues: PAR-24-101 NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- 2 steps back: PAR-20-285 NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- 3 steps back: PAR-18-561 NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01 - Clinical Trial Optional)
- 4 steps back: PAR-17-274 NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01)
- 5 steps back: PAR-14-220 NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01)
Who won it before
20 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $81,859,310 in first-year total cost, median $3,986,475.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-G (33)]3
- Special Emphasis Panel[ZNS1 SRB-G (14)]2
- Special Emphasis Panel[ZNS1 SRB-H (01)]2
- Special Emphasis Panel[ZNS1 SRB-W (01)]2
- Neurological Sciences and Disorders K Study Section[NSD-K]1
Most frequent institutions
- UNIVERSITY OF CINCINNATI4
- STANFORD UNIVERSITY3
- BETH ISRAEL DEACONESS MEDICAL CENTER2
- YALE UNIVERSITY2
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Cilostazol for Prevention of Recurrent Stroke (CLARITY)1UG3NS133209-01A1 · under PAR-24-101 | DE HAVENON, ADAM H.LANSBERG, MAARTEN GSHETH, KEVIN NAVIN | STANFORD UNIVERSITY, CA | $5,747,701 | ZNS1 |
| 2025 | Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial1UG3NS138638-01A1 · under PAR-24-101 | MOCCO, J DUFFYSELIM, MAGDY HYEATTS, SHARON DZIUBA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $2,336,853 | ZNS1 |
| 2024 | Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial (The TR-2 Trial)1UG3NS133283-01A1 · under PAR-20-285 | CRAMER, STEVEN C.EDWARDS, DYLAN JAMES | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $4,408,773 | ZNS1 |
| 2023 | Strategy for Improving Stroke Treatment Response (SISTER) Trial1UG3NS125023-01A1 · under PAR-20-285 | ELM, JORDAN J.KHATRI, POOJAMISTRY, EVAREED, GUY L | UNIVERSITY OF CINCINNATI, OH | $5,110,320 | ZNS1 |
| 2023 | CAPTIVA-MRI1UG3NS130228-01 · under PAR-20-285 | AMIN-HANJANI, SEPIDEHCHATTERJEE, ARINDAM R.DE HAVENON, ADAM H.LIEBESKIND, DAVID SIGMUND | YALE UNIVERSITY, CT | $1,906,569 | ZNS1 |
| 2023 | FOcal Cerebral Arteriopathy Steroids (FOCAS) Trial1UG3NS119702-01A1 · under PAR-20-285 | ELKIND, MITCHELL SFULLERTON, HEATHER J | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,773,264 | ZNS1 |
| 2022 | ZZ-3K3A-301: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (RHAPSODY-2)1UG3NS119199-01A1 · under PAR-20-285 | LYDEN, PATRICK D | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $3,980,070 | ZNS1 |
| 2021 | Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis1U01NS117450-01A1 · under PAR-18-561 | CHIMOWITZ, MARC IVORHOH, BRIAN LIM | UNIVERSITY OF FLORIDA, FL | $8,624,024 | ZNS1 |
| 2021 | Validation of Early Prognostic Data for Recovery Outcomes after Stroke for Future, Higher Yield Trials (VERIFY)1U01NS120910-01 · under PAR-18-561 | CRAMER, STEVEN C.KHATRI, POOJASTINEAR, CATHYVAGAL, ACHALA SAMEER | UNIVERSITY OF CINCINNATI, OH | $3,992,880 | ZNS1 |
| 2021 | StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study1UF1NS120871-01 · under PAR-18-561 | SELIM, MAGDY HSHOAMANESH, ASHKAN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $2,705,364 | ZNS1 |
| 2020 | FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial1U01NS110772-01 · under PAR-18-561 | BRODERICK, JOSEPH PAULELM, JORDAN J.GROTTA, JAMES CNAIDECH, ANDREW M | UNIVERSITY OF CINCINNATI, OH | $6,472,265 | ZNS1 |
| 2019 | Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)1U01NS106513-01A1 · under PAR-18-561 | KAMEL, HOOMANSHETH, KEVIN NAVIN | YALE UNIVERSITY, CT | $4,032,209 | ZNS1 |
| 2019 | StATins Use in intRacerebral hemorrhage patieNts (SATURN)1U01NS102289-01A1 · under PAR-17-274 | SELIM, MAGDY H | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $3,014,650 | ZNS1 |
| 2019 | Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)1U01NS106655-01A1 · under PAR-18-561 | LO, WARREN DAVIDRAMEY, SHARON LANDESMAN | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $2,926,648 | ZNS1 |
| 2019 | ARCADIA CSI (Cognition and Silent Infarcts)1U01NS110728-01 · under PAR-18-561 | LANSBERG, MAARTEN GLAZAR, RONALD M | STANFORD UNIVERSITY, CA | $1,922,432 | ZNS1 |
| 2018 | Sleep for Stroke Management And Recovery Trial (Sleep SMART)1U01NS099043-01A1 · under PAR-14-220 | BROWN, DEVIN LCHERVIN, RONALD D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $7,487,394 | ZNS1 |
| 2018 | Multi-arm Optimization of Stroke Thrombolysis (MOST) Stroke Trial1U01NS100699-01A1 · under PAR-14-220 | ADEOYE, OPEOLU MBARRETO, ANDREW DBRODERICK, JOSEPH PAULGROTTA, JAMES C | UNIVERSITY OF CINCINNATI, OH | $5,966,429 | ZNS1 |
| 2018 | TRANScranial direct current stimulation for POst-stroke motor Recover - a phase II sTudy (TRANSPORT 2)1U01NS102353-01A1 · under PAR-17-274 | FENG, WUWEISCHLAUG, GOTTFRIED | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $2,445,380 | ZNS1 |
| 2017 | AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenicstroke (ARCADIA)1U01NS095869-01A1 · under PAR-14-220 | BRODERICK, JOSEPH PAULELKIND, MITCHELL SKAMEL, HOOMANLONGSTRETH, WTMEINZER, CAITLYN NTIRSCHWELL, DAVID L | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $4,072,827 | NSD |
| 2015 | DEFUSE 3: EnDovascular ThErapy Following Imaging EvalUation for ISchemic StrokE 31U01NS092076-01A1 · under PAR-14-220 | ALBERS, GREGORY W | STANFORD UNIVERSITY, CA | $2,933,258 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.